Horien Biochemical Technology Co., Ltd.

As of June 30, 2026, Horien Biochemical Technology Co., Ltd. carries a market capitalization of 1.71B, placing it among publicly traded companies globally. Its enterprise value stands at 1.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Horien Biochemical Technology Co., Ltd.'s next confirmed earnings release is scheduled for December 14, 2026.

As of June 30, 2026, Horien Biochemical Technology Co., Ltd. has 45.00M shares outstanding.

As of June 30, 2026, Horien Biochemical Technology Co., Ltd. trades at a trailing price-to-earnings ratio of 277.81. The price-to-sales ratio is 15.59, and the price-to-book ratio stands at 5.85.

As of June 30, 2026, Horien Biochemical Technology Co., Ltd. trades at an EV/EBITDA multiple of 126.16 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 14.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 676.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.50B versus a market cap of 1.71B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Horien Biochemical Technology Co., Ltd. maintains a current ratio of 13.01, meaning it holds 13.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.20, indicating conservative leverage, while an interest coverage ratio of 565.95 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Horien Biochemical Technology Co., Ltd. posted a return on equity (ROE) of 1.95, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.76 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.80, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.95, useful for judging operating efficiency across full business cycles. The company generates approximately 1.78M in revenue per employee across its workforce of 56.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.64 indicates how many times Horien Biochemical Technology Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Horien Biochemical Technology Co., Ltd.'s stock has declined approximately 31.56% over the past 52 weeks. The 50-day moving average sits at 29.07, while the 200-day moving average is 36.99.

Over the twelve months ended June 30, 2026, Horien Biochemical Technology Co., Ltd. generated 100.32M in revenue and converted that into 5.63M in net income, yielding earnings per share of 0.14. EBITDA reached 11.89M, while operating income came in at 2.23M.

As of June 30, 2026, Horien Biochemical Technology Co., Ltd. holds 208.93M in cash and equivalents against 597,000.00 in total debt, resulting in a net debt position of -141.03M. Total book value stands at 291.70M, with working capital of 226.15M providing operational flexibility.

Horien Biochemical Technology Co., Ltd. produced 5.22M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.79M in capital expenditures, free cash flow totaled -564,000.00 - equivalent to -0.01 per share.

Over the twelve months ended June 30, 2026, Horien Biochemical Technology Co., Ltd. posted a gross margin of 69.06, reflecting its pricing power and cost economics. The operating margin of 2.22 and net profit margin of 5.61 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.12, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Horien Biochemical Technology Co., Ltd. shareholders.

As of June 30, 2026, Horien Biochemical Technology Co., Ltd. has an Altman Z-Score of 55.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.